Dr. Hamada, MD, MPH, PhD is a gastroenterologist and epidemiologist specializing in pancreatobiliary diseases. He received his MD from The University of Tokyo in 2005 and his PhD from Graduate School of Medicine, The University of Tokyo in 2013. He has conducted clinical and epidemiological research on benign and malignant pancreatobiliary diseases. To advance investigations into prognostic factors and therapeutic targets in pancreatic diseases, Dr. Hamada established and leads large clinical cohorts of patients with pancreatic cancer and pancreatic cysts, known as the GTK (Good To Know) Pancreatic Cancer and TOP-CREATE cohorts, respectively. In the field of intra-pancreatic fat deposition, he recently conducted a case-control study nested into the TOP-CREATE cohort and identified fatty pancreatic disorder as a specific risk factor for carcinoma developing concomitantly with intraductal papillary mucinous neoplasms (Oyama H, Hamada T [corresponding], et al. Gastroenterology 2025 in press). His research interests also include endoscopic treatment of pancreatic fluid collections. As a core member and data manager of the multicenter WONDERFUL (WON and peripancreatic fluid collection) study group, he has contributed to the design and implementation of retrospective and prospective studies, including randomized controlled trials (e.g., WONDER-01 and WONDER-02 trials). Through transdisciplinary collaborations with researchers both within and outside Japan, Dr. Hamada aims to facilitate early detection and develop personalized treatment strategies for pancreatic diseases, ultimately enhancing patient outcomes and quality of life.